
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences Inc is positioned favorably due to its innovative in-house precision medicine platform, SNAP, which enhances the design and prediction of high-potency drug candidates, exemplified by its clinical-stage molecule TYRA-300. The company is set for a significant development period in 2025, with multiple indications for TYRA-300 expected to advance, thereby expanding its pipeline and enhancing potential revenue streams. The clearance of trials for lower doses of TYRA-300 further supports the company’s strategy to address various medical needs, thereby increasing the likelihood of successful therapeutic outcomes and potential market impact.
Bears say
Tyra Biosciences reported a significant net loss of $25.6 million, equating to a loss of $0.43 per share, which closely aligns with prior estimates, indicating potential ongoing financial struggles. The clinical pipeline faces considerable risk, particularly with reliance on the success of TYRA-300, alongside concerns of clinical and regulatory setbacks that could adversely affect revenue projections if the product receives approval. Furthermore, data from competing pan-FGFR inhibitors demonstrate noteworthy safety and efficacy challenges, highlighting the competitive landscape and potential hurdles for the company’s drug candidates, which may further undermine investor confidence.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares